Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

[1]  H. Kantarjian,et al.  A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia , 2012 .

[2]  K. Döhner,et al.  Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364). , 2012 .

[3]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[4]  R. Mesa,et al.  Long‐term outcome of pomalidomide therapy in myelofibrosis , 2012, American journal of hematology.

[5]  A. Tefferi,et al.  Circulating levels of MCP‐1, sIL‐2R, IL‐15, and IL‐8 predict anemia response to pomalidomide therapy in myelofibrosis , 2011, American journal of hematology.

[6]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Barbui,et al.  What are RBC-transfusion-dependence and -independence? , 2011, Leukemia research.

[8]  R. Mesa,et al.  A phase-2 trial of low-dose pomalidomide in myelofibrosis , 2011, Leukemia.

[9]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[10]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[11]  R. Mesa,et al.  Phase1/‐2 study of Pomalidomide in myelofibrosis , 2010, American journal of hematology.

[12]  H. Kantarjian,et al.  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Linch,et al.  In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. , 2009, Blood.

[14]  H. Deeg,et al.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Tefferi,et al.  Erythropoiesis stimulating agents have limited therapeutic activity in transfusion‐dependent patients with primary myelofibrosis regardless of serum erythropoietin level , 2009, European journal of haematology.

[16]  A. Green,et al.  Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones , 2009, British journal of haematology.

[17]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[18]  A. Dalgleish,et al.  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.

[19]  D. Verhelle,et al.  Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. , 2008, Journal of Clinical Investigation.

[20]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[21]  D. Verhelle,et al.  Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. , 2007, Cancer research.

[22]  J. Sloan,et al.  The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients. , 2006 .

[23]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[24]  H. Deeg,et al.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.

[25]  H. Kantarjian,et al.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.

[26]  H. Kantarjian,et al.  Thalidomide therapy for myelofibrosis with myeloid metaplasia , 2006, Cancer.

[27]  J. Rossi,et al.  Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. , 2006, Haematologica.

[28]  A. Tefferi.  Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Hoffman,et al.  Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. , 2005, Blood.

[30]  E. Montserrat,et al.  Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients , 2005, British journal of haematology.

[31]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[33]  P. Musto.  Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. , 2004, Leukemia research.

[34]  M. Le Bousse-Kerdilès,et al.  Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Steensma,et al.  A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. , 2003, Blood.

[36]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[37]  G. Barosi,et al.  Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[38]  F. Wendling,et al.  Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.

[39]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.